Transparency Guidelines
COVID-19
Who We Are
Our Industry
Resources
Login
Publications
Educational Whitepaper: Towards Best Practice in Consumer Involvement in Decisions about Funding Medicines in New Zealand
New Zealand's Medicines Landscape 2020/21
Public Perceptions of Healthcare, Pharmaceuticals and COVID-19 in New Zealand Key Findings of two National Online Surveys April 2021
Funding Medicines in New Zealand: Revision of the Medicines Waiting List to 30 April 2020
New Zealand's Medicines Landscape 2019/20
Public Perceptions of Medicines Funding in New Zealand - Key Findings of two National Online Surveys
Access to Medicines (AtoM 2) Report 2020
NZIER A new generation medicines policy - discussion document
NZIER The value of clinical research with modern medicines in New Zealand
NZIER Establishment of a medicines appropriation
NZIER Rapid access to new medicines in New Zealand
IQVIA International Comparisons of Modern Medicines (ICoMM 2) Report 2020
Funding Medicines in New Zealand: Revision of the Medicines Waiting List to 30 June 2019
IQVIA International Comparisons of Modern Medicines (ICoMM) Report 2019
New Zealand's Medicines Landscape 2018/19
NZIER: Community Pharmaceutical Expenditure Trends
IQVIA Access to Medicines (ATOM) Report 2018
New Zealand's Medicines Waiting List (July 2018)
Modern medicines situational analysis; status and solutions - 2018
New Zealand Medicines Landscape 2017
Medicines NZ Strategic Vision
New Zealand's Medicines Waiting List (February 2017)
The impact of pharmaceutical innovation on New Zealand cancer patients - 2016
New Zealand Medicines Landscape 2016
Funding medicines in New Zealand: Revision of the Medicines Waiting List
Examining medicines: generic or biologic? Patent or data protection?
How to treat - adult vaccination
New Zealand Medicines Landscape 2015
Cancer in New Zealand
Annual Review 2014
Did You Know
Annual Review 2013
